Opdivo demonstrated a significant improvement over chemotherapy, with a 23% reduction in risk of death and a 2.5-month improvement in the median time patients survived, compared to those on chemotherapy. Opdivo’s safety profile was consistent with that reported previously.
Opdivo Superior to Chemotherapy in Patients with Advanced Esophageal Cancer, Trial Shows